Quest Laboratories Ltd
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments[1]
- Market Cap ₹ 168 Cr.
- Current Price ₹ 102
- High / Low ₹ 140 / 75.2
- Stock P/E 11.9
- Book Value ₹ 54.9
- Dividend Yield 0.00 %
- ROCE 26.9 %
- ROE 24.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.7.25 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 104 | 126 | |
| 29 | 53 | 54 | 67 | 88 | 111 | |
| Operating Profit | 1 | 6 | 8 | 16 | 16 | 15 |
| OPM % | 5% | 11% | 13% | 19% | 15% | 12% |
| 0 | 0 | 0 | 0 | 4 | 7 | |
| Interest | 0 | 0 | 1 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 19 | 19 |
| Tax % | 18% | 29% | 28% | 30% | 27% | |
| 1 | 4 | 5 | 10 | 14 | 14 | |
| EPS in Rs | 8.45 | 8.28 | 8.59 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 49% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -4% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 32% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 65 | 74 |
| 3 | 3 | 4 | 5 | 30 | 33 | |
| 9 | 22 | 28 | 27 | 10 | 12 | |
| Total Liabilities | 18 | 35 | 47 | 61 | 122 | 134 |
| 6 | 7 | 10 | 10 | 12 | 16 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 7 | 52 | 53 |
| 12 | 27 | 37 | 44 | 58 | 66 | |
| Total Assets | 18 | 35 | 47 | 61 | 122 | 134 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 1 | 3 | 4 | 3 | -23 | |
| -1 | -2 | -4 | -5 | -44 | |
| 0 | -0 | 0 | 2 | 67 | |
| Net Cash Flow | -0 | 1 | 0 | 0 | -0 |
| Free Cash Flow | -0 | 2 | 1 | 2 | -27 |
| CFO/OP | 103% | 57% | 72% | 46% | -120% |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 108 | 105 |
| Inventory Days | 12 | 9 | 97 | 113 | 99 |
| Days Payable | 119 | 140 | 215 | 144 | 26 |
| Cash Conversion Cycle | 3 | 4 | 1 | 77 | 178 |
| Working Capital Days | 9 | 14 | 27 | 58 | 72 |
| ROCE % | 55% | 47% | 57% | 27% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Capacity Utilization - Liquid Syrup % |
|
||
| Capacity Utilization - ORS Powder % |
|||
| Capacity Utilization - Tablets % |
|||
| Installed Capacity - Dry Syrup Kgs |
|||
| Installed Capacity - Liquid Syrup Lakh Liters |
|||
| Installed Capacity - ORS Powder Tons |
|||
| Installed Capacity - Tablets Crores |
|||
| Active Products Number |
|||
| Capacity Utilization - Dry Syrup % |
|||
| Presence in Indian States Number |
|||
| Production Volume - Syrup Millions |
|||
| Production Volume - Tablets Millions |
|||
| Total Licensed Formulations/Products Number |
|||
| Order Book (Myanmar) INR Crores |
|||
Documents
Announcements
-
Trading Window
30 March 2026 - Trading window closed Apr 1, 2026 until 48 hours after results for quarter/year ended March 31, 2026.
-
Analysts/Institutional Investor Meet/Con. Call Updates
2 March 2026 - Quest Laboratories to present at Arihant Capital Bharat Connect Conference on 6 Mar 2026 via video conference","checklist":["Review announcement content and context","Assess materiality and market sensitivity","Classify …
-
Outcome of Board Meeting
13 February 2026 - Unaudited Q3/9M results to 31-Dec-2025: Total income Rs3,118.41 lacs; PAT Rs402.62 lacs; limited review unmodified.
-
Reply to Clarification- Financial results
9 February 2026 - Submitted revised unaudited financial results for quarter/half-year ended 30 Sep 2025; Board approved on 13 Nov 2025.
-
Clarification - Financial Results
13 January 2026 - Exchange has sought clarification from Quest Laboratories Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
Business Overview:[1][2]
a) QLL specializes in manufacturing a wide range of pharmaceutical formulations, including antibiotics, antimalarials, anti-inflammatories, respiratory medications,
diabetes treatments, and more.
b) Company also produces a wide range of ethical, generic, and over-the-counter (OTC) drugs in various forms, including tablets, liquids, oral powders, ORS, ointments, and external liquids.
c) Quest offers facilities for institutional supplies, domestic ethical products, PCD, Contract manufacturing, and export, with
a focus on a wide range of specialized formulations and molecules
d) The company has 800+ Licensed Formulations, 272+ Active Products, 25cr.+Order Book from Myanmar